|
|
|||||||||
Brief Communications |
1 Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom
2 Department of Nuclear Medicine, Royal Brompton Hospital, London, United Kingdom
ABSTRACT
Inhaled radiolabeled aerosols provide invaluable information about in vivo drug deposition. Here, we report our methodology for radiolabeling and imaging monodisperse pharmacologic aerosols in order to study basic aerosol science concepts of drug delivery within the human airways. Methods: We used a spinning-top aerosol generator to produce 99mTc-labeled monodisperse albuterol sulfate aerosols of 1.5-, 3-, and 6-µm mass median aerodynamic diameter. Results: In vitro Andersen cascade validation data showed that technetium and albuterol were coassociated on each impactor stage for all 3 aerosols, and the radiolabeling process itself did not affect their particle size distributions. Good-quality
-camera scintigraphic images of lung and extrathoracic deposition were obtained within an asthmatic patient. Conclusion: We have successfully radiolabeled and imaged monodisperse albuterol aerosols within the human lungs. This novel technique provides an important tool to relate fundamental concepts of aerosol particle behavior, in vivo deposition, and therapeutic clinical response.
Key Words: lung aerosol deposition ß2-agonist particle size planar scintigraphy
This article has been cited by other articles:
![]() |
O. S. Usmani, M. F. Biddiscombe, and P. J. Barnes Regional Lung Deposition and Bronchodilator Response as a Function of {beta}2-Agonist Particle Size Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1497 - 1504. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |